Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 6.81B | 6.81B | 5.48B | 4.59B | 4.62B | 3.76B |
Gross Profit | 5.53B | 5.97B | 4.61B | 4.00B | 3.91B | 3.19B |
EBITDA | 2.85B | 2.73B | 2.39B | 1.96B | 2.16B | 1.77B |
Net Income | 1.43B | 1.43B | 1.19B | 846.32M | 1.10B | 844.78M |
Balance Sheet | ||||||
Total Assets | 12.74B | 12.74B | 9.83B | 8.53B | 7.13B | 5.41B |
Cash, Cash Equivalents and Short-Term Investments | 2.33B | 2.33B | 1.82B | 2.55B | 2.25B | 2.20B |
Total Debt | 3.20B | 3.20B | 2.59B | 2.48B | 1.83B | 1.41B |
Total Liabilities | 4.74B | 4.74B | 3.23B | 3.07B | 2.44B | 1.82B |
Stockholders Equity | 7.96B | 7.96B | 6.57B | 5.45B | 4.68B | 3.59B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | 1.29B | 953.37M | 397.69M | 356.50M | 975.07M |
Operating Cash Flow | 0.00 | 2.24B | 1.83B | 1.65B | 1.58B | 1.30B |
Investing Cash Flow | 0.00 | -1.82B | -1.42B | -1.10B | -1.23B | -1.30B |
Financing Cash Flow | 0.00 | -520.48M | -445.50M | -419.12M | -305.72M | -487.69M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | ₹107.71B | 71.70 | 0.10% | 22.34% | 20.75% | ||
64 Neutral | ₹108.55B | 70.98 | 0.71% | 12.86% | 10.42% | ||
63 Neutral | ₹26.05B | 32.35 | 0.31% | 13.78% | 32.19% | ||
61 Neutral | ₹93.53B | 252.00 | ― | 16.85% | -29.52% | ||
58 Neutral | ₹34.11B | 26.07 | ― | 22.04% | ― | ||
51 Neutral | $7.43B | -0.36 | -45.45% | 2.27% | 22.98% | -2.34% |
Vijaya Diagnostic Centre Ltd. announced the successful passing of a resolution by its equity shareholders during a court-convened general meeting. The resolution was approved by a majority of shareholders, including both promoter and public shareholders, indicating strong support for the company’s proposed actions. This outcome may positively impact the company’s strategic operations and reinforce its market position.